Parkinson's - Healing Genes


Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Neurologic Bone Marrow Derived Stem Cell Treatment Study (NEST)

Phase: Not Applicable


The Healing Institute in Margate, FL, is conducting a trial utilizing autologous (from the patient’s own body) stem cells to treat the following neurological diseases:

  • Neurologic Disorders
  • Nervous System Diseases
  • Neurodegenerative Diseases
  • Neurological Disorders
  • Stroke
  • Traumatic Brain Injury
  • Cadasil
  • Chronic Traumatic Encephalopathy
  • Cerebral Infarction
  • Cerebral Ischemia
  • Cerebral Stroke
  • Cerebral Hemorrhage
  • Parkinson
  • Multi-System Degeneration
  • MSA – Multiple System Atrophy
  • Progressive Supranuclear Palsy
  • ALS
  • Amyotrophic Lateral Sclerosis
  • Neuropathy
  • Diabetic Neuropathies

The treatment involves aspiration of the bone marrow from the iliac crest (ridge of the hip bone), then those stem cells isolated from the bone marrow are administered to the patient in one of the 2 methods: IV or as a combination of IV + nasal swab.


  • Be 18 years of age and older
  • Have a diagnosis of one of the neurological diseases listed, with 6 months elapsed since onset
  • Be medically cleared for the bone marrow aspiration procedure


  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Surgical recovery of bone marrow aspirate, an outpatient procedure
  3. A delay while the stem cells are derived
  4. Return after a preparation period to receive the stem cells either via IV or IV + nasal swab
  5. Activities of Daily Living (ADL) will be assessed at 3,6 and 12 months following the procedure


The study site is at the Healing Institute in Margate, FL. Map.


Steven Levy, MD  |  203-423-9494  |  [email protected]




MD Stem Cells

The Healing Institute


Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader